Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Estimation of treatment effect under non-proportional hazards and conditionally independent censoring.

Boyd AP, Kittelson JM, Gillen DL.

Stat Med. 2012 Dec 10;31(28):3504-15. doi: 10.1002/sim.5440. Epub 2012 Jul 4.

2.

Tauroursodeoxycholic acid preservation of photoreceptor structure and function in the rd10 mouse through postnatal day 30.

Phillips MJ, Walker TA, Choi HY, Faulkner AE, Kim MK, Sidney SS, Boyd AP, Nickerson JM, Boatright JH, Pardue MT.

Invest Ophthalmol Vis Sci. 2008 May;49(5):2148-55. doi: 10.1167/iovs.07-1012.

3.

Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene.

Chang B, Hawes NL, Pardue MT, German AM, Hurd RE, Davisson MT, Nusinowitz S, Rengarajan K, Boyd AP, Sidney SS, Phillips MJ, Stewart RE, Chaudhury R, Nickerson JM, Heckenlively JR, Boatright JH.

Vision Res. 2007 Mar;47(5):624-33. Epub 2007 Jan 30.

4.

Tool from ancient pharmacopoeia prevents vision loss.

Boatright JH, Moring AG, McElroy C, Phillips MJ, Do VT, Chang B, Hawes NL, Boyd AP, Sidney SS, Stewart RE, Minear SC, Chaudhury R, Ciavatta VT, Rodrigues CM, Steer CJ, Nickerson JM, Pardue MT.

Mol Vis. 2006 Dec 29;12:1706-14.

5.

Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival.

Stea B, Suh JH, Boyd AP, Cagnoni PJ, Shaw E; REACH Study Group.

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1023-30. Epub 2006 Jan 30.

PMID:
16446056
6.

Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.

Suh JH, Stea B, Nabid A, Kresl JJ, Fortin A, Mercier JP, Senzer N, Chang EL, Boyd AP, Cagnoni PJ, Shaw E.

J Clin Oncol. 2006 Jan 1;24(1):106-14. Epub 2005 Nov 28.

PMID:
16314619
7.

Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.

Choy H, Nabid A, Stea B, Scott C, Roa W, Kleinberg L, Ayoub J, Smith C, Souhami L, Hamburg S, Spanos W, Kreisman H, Boyd AP, Cagnoni PJ, Curran WJ.

J Clin Oncol. 2005 Sep 1;23(25):5918-28.

PMID:
16135463
10.

Selection of peptide entry motifs by bacterial surface display.

Taschner S, Meinke A, von Gabain A, Boyd AP.

Biochem J. 2002 Oct 15;367(Pt 2):393-402.

11.

Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus.

Etz H, Minh DB, Henics T, Dryla A, Winkler B, Triska C, Boyd AP, Söllner J, Schmidt W, von Ahsen U, Buschle M, Gill SR, Kolonay J, Khalak H, Fraser CM, von Gabain A, Nagy E, Meinke A.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6573-8. Epub 2002 May 7.

12.

Yersinia enterocolitica can deliver Yop proteins into a wide range of cell types: development of a delivery system for heterologous proteins.

Boyd AP, Grosdent N, Tötemeyer S, Geuijen C, Bleves S, Iriarte M, Lambermont I, Octave JN, Cornelis GR.

Eur J Cell Biol. 2000 Oct;79(10):659-71.

PMID:
11089914
14.

The virulence plasmid of Yersinia, an antihost genome.

Cornelis GR, Boland A, Boyd AP, Geuijen C, Iriarte M, Neyt C, Sory MP, Stainier I.

Microbiol Mol Biol Rev. 1998 Dec;62(4):1315-52. Review.

15.

TyeA, a protein involved in control of Yop release and in translocation of Yersinia Yop effectors.

Iriarte M, Sory MP, Boland A, Boyd AP, Mills SD, Lambermont I, Cornelis GR.

EMBO J. 1998 Apr 1;17(7):1907-18.

16.

LcrG is required for efficient translocation of Yersinia Yop effector proteins into eukaryotic cells.

Sarker MR, Sory MP, Boyd AP, Iriarte M, Cornelis GR.

Infect Immun. 1998 Jun;66(6):2976-9.

17.

Supplemental Content

Support Center